Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 12.63 is in line with its 3-year average of 12.49, around the middle of its 3-year range (0.00–32.67).
As of the fiscal period ended Tuesday, June 30, 2026. 10.05% above its 12-month average of 11.48.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.63.
CURRENT RATIO
12.63
CURRENT RATIO AVG TTM
11.48
CURRENT RATIO AVG 3Y
12.49
CURRENT RATIO AVG 5Y
N/A
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+10.05%
CURRENT VS 3Y AVG
+1.08%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 513 covered companies
CURRENT VS SECTOR MEDIAN
+276.98%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$115.55M
Current Ratio
12.63
TTM Avg
11.48
3Y Avg
12.49
5Y Avg
N/A
Market Cap
$114.00M
Current Ratio
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$117.43M
Current Ratio
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$118.02M
Current Ratio
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$112.88M
Current Ratio
13.55
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
Market Cap
$111.17M
Current Ratio
7.28
TTM Avg
6.67
3Y Avg
7.13
5Y Avg
10.02
Market Cap
$110.75M
Current Ratio
5.68
TTM Avg
5.13
3Y Avg
4.85
5Y Avg
5.20
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $115.55M | 12.63 | 11.48 | 12.49 | N/A |
| Genelux Corporation (GNLX)vs › | $115.69M | 2.39 | 3.50 | 2.69 | 1.97 |
| Coya Therapeutics, Inc. (COYA)vs › | $114.00M | 13.40 | 10.04 | 7.53 | 8.95 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | 3.36 | 3.23 | 4.24 | 6.08 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | 6.49 | 6.44 | 8.52 | 8.53 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $112.88M | 13.55 | 17.30 | 10.78 | 9.73 |
| BGM Group Ltd. (BGM)vs › | $118.63M | 1.25 | 2.31 | 3.27 | 2.89 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 7.28 | 6.67 | 7.13 | 10.02 |
| Apyx Medical Corporation (APYX)vs › | $110.75M | 5.68 | 5.13 | 4.85 | 5.20 |
| Immunic, Inc. (IMUX)vs › | $110.74M | 5.05 | 1.26 | 3.56 | 6.57 |
Current Ratio
12.63
Quick Ratio
12.63
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 12.63 |
| 2026-03-31 | 8.06 |
| 2025-12-31 | 10.61 |
| 2025-09-30 | 12.03 |
| 2025-06-30 | 14.04 |
| 2025-03-31 | 25.86 |
| 2024-12-31 | 15.05 |
| 2024-09-30 | 31.65 |
| 2024-06-30 | 32.67 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 7.50 |
| 2023-09-30 | 0.00 |
